ValiRx has been granted a patent for its lead therapeutic compound VAL201 for the treatment of breast, prostate, breast and ovarian cancer in Australia.
The cancer diagnostics company said VAL201 has shown efficacy in prostate, breast and ovarian cancer as well as addressing endometriosis or hormone induced abnormal cell growth in women.
VAL201, which is currently progressing though clinical development, has been shown to reduce the abnormal endometrial growth, while leaving other hormone-induced activities working normally.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The original patent and technology covering VAL201 is licensed by ValiRx from Cancer Research Technology for use in androgen resistant cancer.
ValiRx has all rights to perform pre-clinical and clinical developments and obtaining regulatory approvals in all territories
"The granting of this latest patent means that ValiRx is able to add to the Company's intellectual property assets and extend its already extensive IP protection for this compound and its intended indications," said Chief Executive Satu Vainikka.
Shares rose 5.26% to 0.50p at 10:13 Thursday.
RD
